Lowenhaupt's embryology-based classification of thymic tumors and the concept of granulomatous thymoma

Rosaí, Juan

doi:10.1002/(sici)1097-0142(19980401)82:7<1209::aid-cncr1>3.0.co;2-a

Cited by 8 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1948, Lowenhaupt proposed an innovative classification, which was rooted in brand-new embryologic concepts that were emerging but introduced novel terms that were further never used in the field [ 13 , 14 ]. Nevertheless, she univocally stated the epithelial derivation of TETs and indicated complete surgical excision as the treatment of choice [ 14 ].…”

Section: Histopathological Classification Of Thymic Epithelial Tumorsmentioning

confidence: 99%

Thymic Epithelial Tumors: An Evolving Field

Kuhn

Pescia

Mendogni

et al. 2023

Life

View full text Add to dashboard Cite

Despite their rarity, thymic epithelial tumors (TETs) have attracted much interest over the years, leading to an impressive number of histological and staging classifications. At present, TETs are divided by the WHO classification into four main subtypes: type A, type AB, and type B thymomas (subdivided into B1, B2, and B3), and thymic carcinomas, going from the more indolent to the most aggressive ones. Among many debated staging proposals, the TNM and the Masaoka–Koga staging systems have been widely accepted and used in routine practice. The four-tiered histological classification is symmetrically mirrored by the molecular subgrouping of TETs, which identifies an A-like and an AB-like cluster, with frequent GTF2I and HRAS mutations; an intermediate B-like cluster, with a T-cell signaling profile; and a carcinoma-like cluster comprising thymic carcinomas with frequent CDKN2A and TP53 alterations and a high tumor molecular burden. Molecular investigations have opened the way to tailored therapies, such as tyrosine kinase inhibitors targeting KIT, mTOR, and VEGFR, and immune-checkpoints that have been adopted as second-line systemic treatments. In this review, we discuss the crucial events that led to the current understanding of TETs, while disclosing the next steps in this intriguing field.

show abstract

Section: Histopathological Classification Of Thymic Epithelial Tumorsmentioning

confidence: 99%

Thymic Epithelial Tumors: An Evolving Field

Kuhn

Pescia

Mendogni

et al. 2023

Life

View full text Add to dashboard Cite

show abstract

“…Confusing concepts and nomenclature about thymoma and other tumors of the thymus were common in the first half of the 20th century 18 . Our purpose is to briefly mention here the “setting” in which the first contributes of Rosai developed.…”

Section: A Brief Historical Background On Thymic Tumors Classificationmentioning

confidence: 99%

Juan Rosai as master of our comprehensive understanding of thymus and thymoma

et al. 2021

View full text Add to dashboard Cite

Summary In this study, the authors report on the activity of Juan Rosai, one of the pathologists most engaged in the definition of cells, diseases and tumors occurring in the thymus and in the mediastinum during the last 60 years. With his morphological skills and tireless interest in clarification of disease patterns, he contributed extraordinarily to expand our knowledge of the mediastinal diseases and to improve our diagnostic approach. He determined extraordinary advances also in trasmission electron microscopy and in immunohistochemistry as powerful diagnostic tools. Moreover, he proposed and promoted, together with an international panel of Pathologists, the World Health Classification of Thymic tumors as a definite progress in our comprehension and diagnostics of thymic epithelial tumors (TET). Our purpose is to review J. Rosai’s achievements in thymic normal structure, in TET and particularly in the entity now definied as “thymoma”, in distinction from the thymic carcinoma. To do this, our narrative will also be based on personal memories, longstanding collaborations and/or friendship with J. Rosai.

show abstract